Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcγRIIIb and MHC class II expression on the phagocytotic neutrophils

Experimental Hematology

Volumn 37, Issue 3, 2009, Pages 309-321

  Shibata Koyama, Mami ^a   Iida, Shigeru ^a   Misaka, Hirofumi ^a   Mori, Katsuhiro ^a   Yano, Keiichi ^a   Shitara, Kenya ^a   Satoh, Mitsuo ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; FC GAMMA RECEPTOR IIIB; FC RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RITUXIMAB; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CANCER PATIENT; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FLOW CYTOMETRY; FUCOSYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; LYMPHOMA CELL; NATURAL KILLER CELL; NEUTROPHIL; PHAGOCYTOSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD CELLS; CELL DEATH; CELLS, CULTURED; FLOW CYTOMETRY; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LYMPHOMA, B-CELL; MICE; NEUTROPHILS; PHAGOCYTOSIS; PROTEIN BINDING; RECEPTORS, IGG;

EID: 59749104215     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.11.006     Document Type: Article

References (32)

1. Cartron G., Dacheux L., Salles G., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99 (2002) 754-758
2. Dall'Ozzo S., Tartas S., Paintaud G., et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 64 (2004) 4664-4469
3. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21 (2003) 3940-3947
4. Gennari R., Menard S., Fagnoni F., et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10 (2004) 5650-5655
5. Kim D.H., Jung H.D., Kim J.G., et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 108 (2006) 2720-2725
6. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1 (2001) 118-129
7. Kanda Y., Yamada T., Mori K., et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 17 (2006) 104-118
8. Shields R.L., Lai J., Keck R., et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J Biol Chem 277 (2002) 26733-26740
9. Shinkawa T., Nakamura K., Yamane N., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278 (2003) 3466-3473
10. Niwa R., Shoji-Hosaka E., Sakurada M., et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhances antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 64 (2004) 2127-2133
11. Niwa R., Hatanaka S., Shoji-Hosaka E., et al. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcγRIIIa functional polymorphism. Clin Cancer Res 10 (2004) 6248-6255
12. Niwa R., Sakurada M., Kobayashi Y., et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 11 (2005) 2327-2336
13. Suzuki A., Niwa R., Saji S., et al. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clin Cancer Res 13 (2007) 1875-1882
14. Iida S., Misaka H., Inoue M., et al. Non-fucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum IgG on antibody-dependent cellular cytotoxicity through its high binding to FcγRIIIa. Clin Cancer Res 12 (2006) 2879-2887
15. Satoh M., Iida S., and Shitara K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther 6 (2006) 1161-1173
16. Ravetch J.V., and Perussia B. Alternative membrane forms of FcγRIII(CD16) on human natural killer cells and neutrophils. J Exp Med 170 (1989) 481-497
17. Daeron M. Fc receptor biology. Annu Rev Immunol 15 (1997) 203-234
18. Wurflein D., Dechant M., Stokmeyer B., et al. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells. Cancer Res 58 (1998) 3051-3058
19. Stockmeyer B., Valerius T., Repp R., et al. Preclinical studies with FcγR bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res 57 (1997) 696-701
20. Elsasser D., Valerius T., Repp R., et al. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood 87 (1996) 3803-3812
21. van der Kolk L.E., de Haas M., Grillo-Lopezn A.J., Baars J.W., and van Oers M.H. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. Leukemia 16 (2002) 693-699
22. Ravetch J.V., and Kinet J.P. Fc receptors. Ann Rev Immunol 9 (1991) 457-492
23. Kerst J.M., de Haas M., van der Schoot, et al. Recombinant granulocyte colony-stimulating factor administration to healthy volunteers: induction of immunophenotypically and functionally altered neutrophils via an effect on myeloid progenitor cells. Blood 82 (1993) 3265-3272
24. Chuang F.Y., Sassaroli M., and Unkeless J.C. Convergence of Fcγ receptor IIA and Fcγ receptor IIIB signaling pathways in human neutrophils. J Immunol 164 (2000) 350-360
25. Selvaraj P., Fifadara N., Nagarajan S., Cimino A., and Wang G. Functional regulation of human neutrophil Fcγ receptors. Immunol Res 29 (2004) 219-229
26. Urlaub G., Mitchell P.J., Kas E., et al. Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions. Somat Cell Mol Genet 12 (1986) 555-566
27. Yamane-Ohnuki N., Kinoshita S., Inoue-Urakubo M., et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 87 (2004) 614-622
28. Nakanuma K., Tanaka Y., Fujino I., Hirayama N., Shitara K., and Hanai N. Dissection and optimization of immune effector function of humanized anti-ganglioside GM2 monoclonal antibody. Mol Immunol 37 (2000) 1035-1046
29. Radsak M., Iking-Konert C., Stegmaier S., Andrassy K., and Hansch G.M. Polymorphonuclear neutrophils as accessory cells for T-cell activation: major histocompatibility complex class II restricted antigen-dependent induction of T-cell proliferation. Immunology 101 (2000) 521-530
30. Gosselin E.J., Wardwell K., Rigby W.F., and Guyre P.M. Induction of MHC class II on human polyphomorphonuclear neutrophils by granulocyte/macrophage colony-stimulating factor, IFN-gamma, and IL-3. J Immunol 151 (1993) 1482-1490
31. Harding C.V., Ramachandra L., and Wick M.J. Interaction of bacteria with antigen presenting cells: influences on antigen presentation and antibacterial immunity. Curr Opin Immunol 15 (2003) 112-119
32. Roevre P., Vallinoto C., Bondanza A., et al. Cutting edge: bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 161 (1998) 4467-4471